共查询到20条相似文献,搜索用时 156 毫秒
1.
Atkinson MA Lestz RM Fivush BA Silverstein DM 《Pediatric nephrology (Berlin, Germany)》2011,26(12):2219-2226
Published data on the comparative achievement of The Kidney Disease Dialysis Outcome Quality Initative (KDOQI) recommended
clinical performance targets between children and young adults on dialysis are scarce. To characterize the achievement of
KDOQI targets among children (<18 years) and young adults (18–24 years) with prevalent end stage renal disease (ESRD), we
performed a cross-sectional analysis of data collected by the Mid-Atlantic Renal Coalition, in conjunction with the 2007 and
2008 ESRD Clinical Performance Measures Projects. Data on all enrolled pediatric dialysis patients, categorized into three
age groups (0–8, 9–12, 13–17 years), and on a random sample of 5% of patients ≥18 years in ESRD Network 5 were examined for
two study periods: hemodialysis (HD) data were collected from October to December 2006 and from October to December 2007 and
peritoneal dialysis (PD) data were collected from October 2006 to March 2007 and from October 2007 to March 2008. In total,
114 unique patients were enrolled the study, of whom 41.2% (47/114) were on HD and 58.8% (67/114) on PD. Compared to the pediatric
patients, young adults were less likely to achieve the KDOQI recommended serum phosphorus levels and serum calcium × phosphorus
product values, with less than one-quarter demonstrating values at or below each goal. Multivariate analysis revealed that
both young adults and 13- to 17-year-olds were less likely to achieve target values for phosphorus [young adults: odds ratio
(OR) 0.04, 95% confidence interval (95% CI) 0.01–0.19, p < 0.001; 13- to 17-year-olds: OR 0.17, 95% CI 0.04–0.77, p = 0.02] and calcium × phosphorus product (young adults: OR 0.01, 95% CI 0.002–0.09, p < 0.001; 13- to 17-year-olds: OR 0.09, 95% CI 0.02–0.56, p = 0.01) than younger children. In summary, there are significant differences in clinical indices between pediatric and young
adult ESRD patients. 相似文献
2.
Silva JM Diniz JS Silva AC Azevedo MV Pimenta MR Oliveira EA 《Pediatric nephrology (Berlin, Germany)》2006,21(9):1285-1292
The aim of this retrospective cohort study was to evaluate independent predictive factors of chronic kidney disease (CKD) in children with severe bilateral primary vesicoureteral reflux (VUR). Between 1970 and 2004, 184 patients were diagnosed with VUR (grades III–V) and were systematically followed up at a single tertiary renal unit. CKD was defined as estimated glomerular filtration rate <75 ml/min per 1.73 m2 body surface area in two consecutive examinations. Risk of CKD was analyzed by the Kaplan–Meier method and Cox’s regression model. The probability of CKD for patients with bilateral severe reflux was estimated at 15% by 10 years after VUR diagnosis. After adjustment, four variables remained independently associated with CKD during follow-up: age at diagnosis >24 months [relative risk (RR)=4.8, 95% confidence interval (95%CI), 1.8–12.7, P<0.001], VUR grade V (RR=3.5, 95%CI, 1.5–7.9, P=0.002), bilateral renal damage (RR=2.86, 95%CI, 1.3–6.1, P=0.007), and decade of admission after 1990 as a protective factor (RR=0.16, 95%CI 0.06–0.43, P<0.001). A delay in the diagnosis of VUR more than 12 months after urinary tract infection (UTI) was also a predictive factor in an alternative model (RR=2.2, 95%CI, 1.1–6.6, P=0.03). Prognosis regarding renal function was relatively poor after a long-term follow-up of patients with bilateral severe reflux. 相似文献
3.
Whilst it is assumed that body growth is retarded in children with steroid-resistant nephrotic syndrome (NS), the degree of
growth failure and the pathomechanisms involved are poorly understood. We collected serial growth data in 45 children (24
males) with steroid-resistant NS usually from onset to end-stage renal disease (ESRD) during childhood (n=10) or until final height was attained (n=27). Mean follow-up time was 9 (2–19) years. Mean initial standardized height was –0.3±1.2 standard deviation scores (SDS).
Mean final height was +0.4 SDS in males and –1.0 SDS in females (sex difference not significant). In 16 patients with serum
creatinine levels consistently <1.2 mg/dl, mean final height SDS was 0.3 SDS higher than that obtained within 6 months of
onset. In contrast, 9 children who entered ESRD lost an average of 1.3 SDS from the initial record to ESRD (P=0.017). In prepubertal patients without renal insufficiency, mean height SDS decreased during corticosteroid treatment by
0.3 SDS, followed by a partial catch-up after discontinuation of treatment; the change from initial to final height SDS was
inversely correlated with the total prednisone dose given (r=–0.50, P=0.03). In 16 prepubertal children with serial height and serum protein measurements who were off steroids and maintained
normal creatinine levels, mean individual albumin concentrations correlated with the change in height SDS per year (r=0.65, P=0.0006) and in boys with final height (r=0.73, P=0.03). In conclusion, growth in steroid-resistant NS depends on the preservation of renal function, the cumulative dose of
steroids applied, and the severity of hypoproteinemia.
Received: 15 July 1998 / Revised: 30 November 1998 / Accepted: 11 December 1998 相似文献
4.
Eighteen years experience in pediatric acute dialysis: analysis of predictors of outcome 总被引:3,自引:0,他引:3
Gong WK Tan TH Foong PP Murugasu B Yap HK 《Pediatric nephrology (Berlin, Germany)》2001,16(3):212-215
This study reviewed the 18-year experience of acute dialysis in the pediatric intensive care unit, in order to identify factors
that could predict outcome, and to determine whether newer modalities of acute dialysis have influenced this outcome. Sixty-six
children (ages 1 day to 19 years) received acute dialysis from May 1980 to April 1998. Factors predicting outcome were analyzed
using univariate and Cox regression analysis. Modality of dialysis in the first 15 years was exclusively peritoneal dialysis,
with a mortality of 63.9%. However, in the last 3 years, with increasing patient numbers, continuous hemodiafiltration (CHDF)
was the modality of choice (56.7%), with a mortality of 73.3%. Univariate analysis showed that age <1 year, coma, acute tubular
necrosis, disseminated intravascular coagulopathy, assisted ventilation, and hypotension were associated significantly with
poor outcome (P<0.05). Cox regression analysis revealed that mortality was significantly higher in patients on mechanical ventilation (RR
5.96, 95% CI 1.82–19.50), or with age <1 year (RR 2.00, 95% CI 1.08–3.73). In conclusion, despite the increasing use of CHDF
over the last 3 years, there was no significant improvement in mortality, probably related to the fact that more critically
ill patients were dialyzed.
Received: 21 March 2000 / Revised: 12 October 2000 / Accepted: 19 October 2000 相似文献
5.
Vestergaard P Mollerup CL Frøkjaer VG Christiansen P Blichert-Toft M Mosekilde L 《World journal of surgery》2003,27(2):216-222
Abstract
Cardiovascular disease [atherosclerosis and subsequent myocardial infarction (MI)] has been associated with primary hyperparathyroidism.
We aimed at studying cardiovascular events before and after surgery and mortality after surgery for primary hyperparathyroidism
using a historical follow-up design. A total of 674 patients who underwent surgery at three Danish centers between January
1, 1979 and December 31, 1997 were compared with 2021 age- and gender-matched controls. There was an increased incidence of
acute MI up to 10 years prior to surgery [relative risk (RR) 2.5, 95% confidence interval (95% CI) 1.5–4.2] and within the
first year following surgery (RR 3.6, 95% CI 1.7–7.6). The risk of MI subsequently declined to a normal level more than 1
year after surgery. Patients with MI prior to diagnosis also had a higher postoperative risk of new infarction than did patients
without [odds ratio (OR) 6.0, 95% CI 1.2–30.0]. The risk of hypertension, stroke, congestive heart failure, and diabetes was
increased before surgery. More than 1 year after surgery only hypertension and congestive heart failure were more frequent
in patients than controls. Preoperative cardiovascular disease was associated with an increased risk of death (RR 1.8, 95%
CI 1.1–2.8). Mortality following surgery was higher than in the general population between 1979 and 1990 but not between 1991
and 1997. We concluded that there was an increase in acute MI up to 10 years prior to surgery. The risk of MI decreased to
a normal level after surgery, which may be important for preventing cardiovascular disease in patients with primary hyperparathyroidism. 相似文献
6.
BACKGROUND: It is hypothesized, but not proven, that peritoneal dialysis might be the optimal treatment for end-stage renal disease (ESRD) patients with established congestive heart failure (CHF) through better volume regulation compared with hemodialysis. METHODS: National incidence data on 107,922 new ESRD patients from the Center for Medicare and Medicaid Services (CMS) Medical Evidence Form were used to test the hypothesis that peritoneal dialysis was superior to hemodialysis in prolonging survival of patients with CHF. Nonproportional Cox regression models evaluated the relative hazard of death for patients with and without CHF by dialysis modality using primarily the intent-to-treat but also the as-treated approach. Diabetics and nondiabetics were analyzed separately. RESULTS: The overall prevalence of CHF was 33% at ESRD initiation. There were 27,149 deaths (25.2%), 5423 transplants (5%), and 3753 (3.5%) patients lost to follow-up over 2 years. Adjusted mortality risks were significantly higher for patients with CHF treated with peritoneal dialysis than hemodialysis [diabetics, relative risk (RR) = 1.30, 95% confidence interval (CI) 1.20 to 1.41; nondiabetics, RR = 1.24, 95% CI 1.14 to 1.35]. Among patients without CHF, adjusted mortality risk were higher only for diabetic patients treated with peritoneal dialysis compared with hemodialysis (RR = 1.11, 95% CI 1.02 to 1.21) while nondiabetics had similar survival on peritoneal dialysis or hemodialysis (RR = 0.97, 95% CI 0.91 to 1.04). CONCLUSION: New ESRD patients with a clinical history of CHF experienced poorer survival when treated with peritoneal dialysis compared with hemodialysis. These data suggest that peritoneal dialysis may not be the optimal choice for new ESRD patients with CHF perhaps through impaired volume regulation and worsening cardiomyopathy. 相似文献
7.
Urologic disorders are the most common cause of chronic kidney disease in children. To determine whether children with urologic
etiology of end-stage renal disease (ESRD) fare better than children with ESRD from other causes while on dialysis, we conducted
a cross-sectional study of children <18 years receiving peritoneal and hemodialysis in the United States using data from the
Centers for Medicare & Medicaid Services 2005 ESRD CPM Project. We compared baseline demographics and the study groups. In
multivariate logistic regression analysis of 1,286 subjects, we assessed whether children with urologic disorders had a higher
odds of meeting adult KDOQI targets for hemoglobin levels ≥11 g/dl and albumin ≥3.5 BCG/3.2 BCP g/dl. We conducted a subset
analysis of 1,136 patients to examine the impact of erythropoietin on hemoglobin targets. Our results did not reveal differences
in achievement of adult hemoglobin targets (adjusted OR: 1.27; p value 0.09; CI: 0.97–1.66) or in the subset analysis with erythropoietin (adjusted OR: 1.32; p value 0.06; CI: 0.98–1.78) or albumin targets (adjusted OR: 1.22; p value 0.21; CI: 0.90–1.65) in adjusted analyses. Due to our study’s limitations, it is difficult to determine whether this
may result from treatment prior to dialysis initiation or treatment effect of dialysis rather than underlying diagnosis. 相似文献
8.
Gorman G Fivush B Frankenfield D Warady B Watkins S Brem A Neu A 《Pediatric nephrology (Berlin, Germany)》2005,20(12):1794-1800
End-stage renal disease (ESRD) causes growth retardation in children, and poor growth has been linked to worse outcomes. Recombinant human growth hormone (rhGH) can increase growth velocity and final adult height in pediatric ESRD patients. We aimed to identify clinical predictors of short stature (height standard deviation score (Ht SDS) <-1.88) and rhGH use in short stature pediatric hemodialysis patients. In 2002, the Centers for Medicare & Medicaid Services (CMS) Clinical Performances Measures (CPM) ESRD Project collected demographic, clinical and laboratory data as well as rhGH use on all in-center hemodialysis patients in the US aged <18 years. The odds ratios (OR) of short stature and rhGH use for individual predictors were determined by multivariate logistic regression modeling. Six-hundred and fifty-one (92%) of 710 eligible patients were included for analysis. Of these, 266 (41%) had Ht SDS <-1.88. After adjustment, short stature was predicted by congenital/urologic causes of ESRD ((OR 5.4; 95% confidence interval [CI], 2.1-13.8; p <0.001) in patients aged 10-14 years; (OR 2.8; 95% CI, 1.5-5.4; p <0.01) in patients aged 15-18 years) and increasing years on dialysis ((OR 1.2; 95% CI, 1.1-1.4; p <0.01) in patients aged 10-14 years; (OR 1.2; 95% CI, 1.1-1.4; p <0.001) in patients aged 15-18 years). Of 266 short stature patients, 214 (80.5%) had data on rhGH use. Of these, 80 (37%) had been prescribed rhGH. After adjustment, use of rhGH in short-stature patients was predicted by white race (OR 2.1; 95% CI, 1.1-4.0; p <0.05), increasing years on dialysis (OR 1.13; 95% CI, 1.05-1.22; p <0.01) and patients with BMI <16.6 kg/m(2) (OR 3.1; 95% CI, 1.2-8.4; p <0.05). Increasing age and level of intact parathyroid hormone were not associated with rhGH use among short stature patients. A significant proportion of pediatric hemodialysis patients have short stature. The majority of short-stature patients are not receiving rhGH. Patients with short stature who are white, have longer durations on dialysis and have lower BMI are more likely to receive rhGH. 相似文献
9.
Comparison of mortality risk for dialysis patients and cadaveric first renal transplant recipients in Ontario, Canada 总被引:8,自引:0,他引:8
Rabbat CG Thorpe KE Russell JD Churchill DN 《Journal of the American Society of Nephrology : JASN》2000,11(5):917-922
In population-based studies, renal transplantation has been shown to improve survival compared to dialysis patients awaiting transplantation in the United States. However, dialysis mortality in the United States is higher than in Canada. Whether transplantation offers a survival advantage in regions where dialysis survival is superior to that in the United States is uncertain. This study examines a cohort of 1156 patients who started end-stage renal disease (ESRD) therapy and were wait-listed for cadaveric renal transplantation in the province of Ontario, Canada between January 1, 1990 and December 31, 1994. Patients were followed from wait-listing for renal transplant (n = 1156), to cadaveric first renal transplant (n = 722), to death, or to study end (December 31, 1995). The annual crude mortality rates for wait-listed dialysis patients and transplanted patients were 5.0 and 3.4%, respectively. In Cox proportional hazards models, mortality in wait-listed patients was associated with increased age and diabetes, but not time from onset of ESRD to wait-listing. Factors associated with death following transplantation include older age, diabetes, and longer time spent on the waiting list before transplantation. In a time-dependent Cox regression model, the relative risk of death after transplantation compared to dialysis varied in a time-dependent manner. Covariates associated with increased risk included older age, diabetes, and time from onset of ESRD to wait-listing. The average relative risk (RR) of dying was 2.91 (95% confidence interval [CI], 1.34 to 6.32) in the first 30 d after transplantation, but was significantly lower 1 yr after transplantation (RR 0.25; 95% CI, 0.14 to 0.42), indicating a beneficial long-term effect when compared to wait-listed dialysis patients. This long-term benefit was most evident in subgroups of patients with diabetes (RR 0.38; 95% CI, 0.17 to 0.87) and glomerulonephritis (RR 0.13; 95% CI, 0.04 to 0.39) as the cause of ESRD. The survival advantage associated with renal transplantation is evident in this cohort of patients with a lower wait-listed dialysis mortality than that reported previously in the United States. The magnitude of the treatment effect is consistent across studies. 相似文献
10.
Seikaly MG Salhab N Warady BA Stablein D 《Pediatric nephrology (Berlin, Germany)》2007,22(8):1195-1204
We evaluated the utilization and potential benefits of recombinant human growth hormone (rhGH) in children with chronic kidney
disease (CKD) and following renal transplantation in a large patient cohort. We queried the chronic renal insufficiency (CRI),
dialysis, and transplant registries of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) to characterize
the frequency of rhGH utilization, factors related to its usage, and the relationship between rhGH usage and catch-up growth.
Data from 6,505, 5,122, and 4,478 CRI, dialysis, and transplant patients, respectively, was evaluated. Percentage utilization
of rhGH 2 years after registry entry was 22%, 33%, and 3% in children with a height standard deviation score (SDS) <−1 and
age <17 years (termed candidate group) in CRI, dialysis, and transplant patients, respectively. Multivariate logistic regression
analysis showed that the likelihood of using rhGH was significantly correlated with age, gender, geographical region of residence
and height category within the candidate group (p < 0.01). The use of rhGH was associated with catch-up growth in 27%, 11%, and 25% of candidate CRI, dialysis, and transplant
patients, respectively. In the candidate group, percentage catch-up growth was highest in children who were Tanner stage 1–2,
who comprised 19.4%, 7.1%, and 25.5% of the CRI, dialysis, and transplant patients, respectively. Using multiple regression
analysis, the estimated impact of rhGH on final adult height (age >19 years) was 0.80, 0.50, and 0.19 SDS, in CRI, dialysis,
and transplant patients, respectively. Thus, rhGH can improve height gain in some children with CKD. The use of rhGH appears
to be most effective in prepubertal children with CRI. 相似文献
11.
Meredith A. Atkinson Pooja C. Oberai Alicia M. Neu Barbara A. Fivush Rulan S. Parekh 《Pediatric nephrology (Berlin, Germany)》2010,25(6):1153-1161
There have been no studies in pediatric dialysis patients to evaluate the impact of higher estimated glomerular filtration
rate (eGFR) at dialysis initiation on clinical outcomes. Baseline clinical and demographic information was collected for children
aged 1–18 years undergoing incident dialysis from 1995–2002 within the United States Renal Data System. Baseline eGFRs calculated
by the Schwartz formula were categorized as high (>15 ml/min/1.73 m2) or low (≤15 ml/min/1.73 m2). We determined predictors of eGFR at baseline, and associations between baseline eGFR and subsequent hospitalization for
hypertension (HTN) or pulmonary edema (PE) in a longitudinal nonconcurrent pediatric end-stage renal disease (ESRD) cohort.
Twenty percent of children had a high eGFR at initiation. Black children were less likely to initiate dialysis with a high
eGFR [adjusted odds ratio (adjOR) 0.71, p < 0.001]. Girls were less likely to have a high eGFR at baseline (adjOR 0.71, p < 0.001). Children who received predialysis erythropoietin therapy were more likely to start dialysis with a high eGFR (adjOR
6.67, p < 0.001). Children with higher baseline eGFR were found to have a 21% decreased risk of hospitalization [adjusted hazard
ratio (HR) 0.79, 95% confidence interval (CI) 0.65–0.96, p = 0.02]. It is not known whether this clinical benefit will result in decreased mortality and complication rates from cardiovascular
disease. 相似文献
12.
BACKGROUND: It has been hypothesized that peritoneal dialysis compared to hemodialysis may be less effective in large patients with end-stage renal disease (ESRD). METHODS: We tested this hypothesis in a cohort of 134,728 new ESRD patients who were initiated on dialysis from May 1, 1995 to July 31, 1997 using data from United States Renal Data System (USRDS). Cox regression models evaluated the association of body mass index (BMI) in quintiles (8.8-20.9, 20.9-23.5, 23.5-26.1, 26.1-30.0, 30.0-75.2 kg/m(2)) with mortality over 2 years in peritoneal dialysis and hemodialysis patients separately, while time-dependent models evaluated the relative risk (RR) of death by modality for each BMI quintile. RESULTS: For hemodialysis, the adjusted RR of death was greatest for patients with BMI 30.0 (RR = 0.97, 95% CI 0.96-0.99 for diabetic and RR = 0.97, 95% CI 0.95-0.98 for nondiabetic patients) compared with the referent (23.5-26.1; RR = 1.00). For peritoneal dialysis, the RR of death was also higher for patients with a BMI <20.9 (RR = 1.20, 95% CI 1.00-1.43 for diabetic and RR = 1.39, 95% CI 1.19-1.64 for nondiabetic patients) but no survival advantage was associated with higher BMI values. The RR of death (peritoneal dialysis/hemodialysis) for each BMI quintile was 0.99, 1.12, 1.26 (P < 0.01), 1.15 (P < 0.01), and 1.44 (P < 0.0001) for diabetic and were 1.07, 1.01, 0.96, 1.04, and 1.22 (P < 0.01) for nondiabetic patients, respectively. CONCLUSION: We conclude that body size modifies the impact of dialysis modality on mortality risk among new ESRD patients in the United States. The selection of hemodialysis over peritoneal dialysis was associated with a survival advantage in patients with large body habitus. 相似文献
13.
To identify demographic and clinical characteristics associated with failure to achieve hemoglobin levels 11 g/dl in prevalent pediatric end-stage renal disease (ESRD) patients, a cross-sectional analysis of patient clinical data collected by the Mid-Atlantic Renal Coalition in conjunction with the 2000 and 2001 ESRD Clinical Performance Measures Projects was performed. Ninety-nine patients (mean age 12.6 years, SD 5.4) contributed 119 observations to this analysis. Of patients on hemodialysis, 36.6% were anemic, and 39.5% of patients on peritoneal dialysis (PD) were anemic. Associations between age, race, gender, assigned cause of ESRD, Kt/V, transferrin saturation, time on dialysis, serum albumin, dialysis modality, and the achievement of target hemoglobin were examined. In multivariate logistic regression analyses examining age, dialysis modality, time on dialysis, and serum albumin, each 1-year increase in age was significantly associated with hemoglobin levels <11 g/dl [adjusted odds ratio (OR) 1.18, 95% confidence interval (CI) 1.06–1.32] and PD patients were more than twice as likely to have hemoglobin levels <11 g/dl (adjusted OR 2.62, 95% CI 0.98–7.04). Patients on dialysis for 6 months or more were less likely to be anemic than those on dialysis for less than 6 months (adjusted OR 0.39, 95% CI 0.16–0.99). In conclusion, increasing age, dialysis for less than 6 months, and treatment with PD were predictive of anemia in this population. 相似文献
14.
Gipson DS Kausz AT Striegel JE Melvin TR Astrom LJ Watkins SL 《Pediatric nephrology (Berlin, Germany)》2001,16(1):29-34
Recombinant human growth hormone (GH) therapy has been shown to be effective in the treatment of growth failure related to
growth hormone resistance among children with chronic renal failure. The traditional route of administration is subcutaneous
injection. This study was designed to evaluate the effectiveness and tolerability of intraperitoneal (IP) administration of
GH in prepubertal peritoneal dialysis patients. Nine subjects were enrolled. Eight completed 24 months of therapy with GH.
Baseline height standard deviation scores (SDS) and growth velocity for the prior year were used for comparison. Peak serum
GH was achieved 4 h after administration and serum half-life was 4.6 h. Mean height SDS was –3.1 at baseline, –2.5 at 1 year,
and –2.3 at 2 years (NS) of GH therapy. Mean height velocity increased from a baseline of 4.6 cm/yr to 8.5 cm/yr in year 1
(P<0.05) and 6.1 cm/yr in year 2 (NS) of IP GH therapy. Peritonitis infection rates were not increased from overall center
rates. This research suggests that the intraperitoneal route of administration of GH can be utilized in the treatment of short
stature among children requiring maintenance peritoneal dialysis therapy.
Received: 8 February 1999 / Revised: 24 May 2000 / Accepted: 25 May 2000 相似文献
15.
Trombetti A Stoermann C Robert JH Herrmann FR Pennisi P Martin PY Rizzoli R 《World journal of surgery》2007,31(5):1014-1021
Background Patients with end-stage renal disease (ESRD) and secondary hyperparathyroidism (SHPT) are at high risk of mortality. Whether
an increased risk of death persists after a parathyroidectomy (PTX) is not clearly established.
Subjects and methods The survival of 40 patients with ESRD and SHPT who underwent PTX was compared with that of 664 ESRD patients.
Results From first dialysis, a lower mortality rate was found in the group of patients who underwent PTX than in the nonoperated ESRD
group (hazard ratio: 0.23; 95% CI: 0.14–0.37). The patients who underwent PTX were younger, had a longer time on dialysis,
and had a higher prevalence of kidney transplantation. The mean number of comorbidities was lower (Charlson score 4.2 ± 2.1
versus 6.4 ± 2.9, p < 0.001). Then, we randomly selected two matched controls for each PTX case (80 controls, 40 PTX) who had at least an equivalent
mean duration of dialysis between the first dialysis and PTX of the PTX group. In a univariate model, there was a trend for
PTX being associated with prolonged survival. The mortality was higher both among those at an advanced age and those with
a high Charlson score. Adjustments for these covariates made the effect of PTX no more significant.
Conclusions The risk of death of patients with severe SHPT leading to PTX differed from that of nonoperated subjects. The apparent differences
in survival may be related to the number and severity of associated comorbidities. ESRD patients who undergo PTX may represent
a subset of healthier subjects. 相似文献
16.
Predictive factors of chronic kidney disease in primary focal segmental glomerulosclerosis 总被引:1,自引:0,他引:1
Abrantes MM Cardoso LS Lima EM Penido Silva JM Diniz JS Bambirra EA Oliveira EA 《Pediatric nephrology (Berlin, Germany)》2006,21(7):1003-1012
Renal histological features of focal segmental glomerulosclerosis (FSGS) are found in 75% of pediatric patients with steroid-resistant nephrotic syndrome. In order to evaluate the predictive factors of chronic kidney disease (CKD), we retrospectively reviewed the records of 110 children with biopsy-proven FSGS admitted between 1972 and 2004. Renal survival was analyzed by the Kaplan–Meier method and Cox’s regression model. Two multivariate models were developed: (1) from the onset of symptoms to the occurrence of CKD and (2) from the time of renal biopsy to CKD. Mean follow-up time was 10 years [standard deviation ((SD) 5.5], and 24 patients (21.8%) progressed to CKD. At baseline, after adjustment three variables remained as independent predictors of CKD: age >6.5 years (RR=3.3, 95% CI=1.3–7.8), creatinine >1 mg/dl (RR=2.5, 95% CI=0.97–6.5), and non-response to steroids (RR=7.3, 95% CI=2.7–19.7). In a model with continuous variables only age and non-response to steroids were associated with CKD. At the time of renal biopsy, after adjustment two variables remained as independent predictors of CKD: hematuria (RR=3.0, 95% CI=1.2–7.3) and creatinine >0.8 mg/dl (RR=4.3, 95% CI=1.7–10.6). In a model with continuous variables four factors predicted CKD: age, creatinine, hematuria, and percentage of global sclerosis. 相似文献
17.
In a systematic review and meta-analysis of randomized controlled trials (RCT), we aimed to evaluate the benefits and harms of all interventions for children with steroid-resistant nephrotic syndrome (SRNS). Nine RCTs involving 225 children were included. Cyclosporin when compared with placebo or no treatment significantly increased the number of children who achieved complete remission [3 trials, 49 children, relative risk (RR) for persistent nephrotic syndrome 0.64, 95% confidence intervals (CI), 0.47–0.88]. There was no significant difference in the number of children who achieved complete remission between oral cyclophosphamide with prednisone and prednisone alone [2 trials, 91 children, RR 1.01, 95% CI 0.74–1.36], between intravenous cyclophosphamide and oral cyclophosphamide [1 study, 11 children, RR 0.09, 95% CI 0.01–1.39], and between azathioprine with prednisone and prednisone alone [1 trial, 31 children, RR 1.01, 95% CI 0.77–1.32]. No RCTs were identified comparing combination regimens comprising high-dose steroids, alkylating agents or cyclosporin with single agents, placebo, or no treatment. Further adequately powered and well-designed RCTs are needed to confirm the efficacy of cyclosporin and to evaluate regimens of high-dose steroids with alkylating agents or cyclosporin for SRNS. 相似文献
18.
Ming Liu Zhiming Yang Fuxing Pei Fuguo Huang Shiqiang Chen Zhou Xiang 《International orthopaedics》2010,34(3):323-328
The objective of this meta-analysis was to compare the fixation outcome of the Gamma nail and dynamic hip screw (DHS) in treating
peritrochanteric fractures. Relevant randomised controlled studies were included, and the search strategy followed the requirements
of the Cochrane Library Handbook. Methodological quality was assessed and data were extracted independently. Seven studies
involving 1,257 fractures were included which compared the effect of the Gamma nail and DHS. The results showed a higher rate
of postoperative femoral shaft fracture with the Gamma nail compared to the DHS [relative risk (RR): 7.27, 95% confidence
interval (CI): 2.83–18.70, P < 0.0001] but no statistical differences in wound infection (RR: 1.02, 95% CI: 0.56–1.86), mortality (RR: 1.00, 95% CI: 0.81–1.24),
re-operation (RR: 1.64, 95% CI: 0.91–2.95) and walking independently after rehabilitation (RR: 0.89, 95% CI: 0.60–1.33). It
seemed that there were no obvious advantages of the Gamma nail over the DHS in treating peritrochanteric fractures. 相似文献
19.
Growth and PTH in prepubertal children on long-term dialysis 总被引:1,自引:1,他引:0
Growth failure is an important complication for children on dialysis. One possible influence on growth is renal bone disease.
We reviewed the case notes of 35 children (23 boys), mean (range) age at inclusion 2.8 (0.25–8.9) years (17 children age <2 years),
on dialysis for 2.0 (1–4.8) years, for growth, PTH, calcium and phosphate levels and medications. Data collection ended at
age 10 years, commencement of growth hormone (rhGH) or renal transplantation. The mean (range) height standard deviation score
(HtSDS) at the start of dialysis was −2.06 (−5.90 to 0.63). No change in HtSDS per year was observed; the median was −0.06
(−1.07 to 2.39). Children aged <2 years showed catch-up growth in the first year on dialysis; median change in HtSDS was 0.31
(−0.78 to 3.13). Mean plasma calcium and ionised calcium were approximately at the mid-point and phosphate just above the
mid-point of the respective normal ranges. The median PTH level was 1.52 times the upper limit of normal and levels did not
correlate with growth. Our results indicate that intensive nutritional therapy and phosphorus control aiming to keep PTH within
the normal range prevents further loss of HtSDS in short children on dialysis. In some children under 2 years of age catch-up
growth can be observed in the first dialysis year. 相似文献
20.
Ellis EN Yiu V Harley F Donaldson LA Hand M Warady BA Wood EG;North American Pediatric Renal Transplant Cooperative Study 《Pediatric nephrology (Berlin, Germany)》2001,16(5):404-408
Supplemental feedings are commonly recommended for young children on dialysis but their effect on growth parameters and mortality
has not been well documented. We report the results of a North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)
survey on the impact of supplemental feedings on growth and mortality in children <6 years of age at dialysis initiation.
Sixty-four nonsurvivors (NonS) were matched with 110 survivors (S) for age at dialysis initiation, primary renal disease,
and year of entry into the NAPRTCS database. Questionnaires were completed by participating centers on 137 patients (51 NonS,
86 S). Supplemental feedings were given to 70% of patients and more commonly given to patients <2 years of age compared to
those 2–5 years of age at dialysis initiation (P<0.001). Supplemental feedings were also more commonly given to patients with nonrenal disease in addition to renal disease
compared to those with renal disease only (P<0.001). In patients receiving supplemental feedings, the method of supplemental feeding was most commonly by nasogastric
tube in patients <2 years of age compared to those 2–5 years of age (P=0.027). Supplemental feeding use was not different in S compared to NonS. There were no differences in height standard deviation
score (SDS), weight SDS, or change in height or weight SDS in patients receiving supplemental feedings compared to those who
did not. The height and weight SDS did not improve over time on supplemental feeds. In summary, despite the common use of
supplemental feedings in young patients on dialysis, height, weight, and mortality remain unaffected. Prospective long-term
evaluation of this therapy is needed to determine the effectiveness of supplemental feeding.
Received: 8 May 2000 / Revised: 20 November 2000 / Accepted: 21 November 2000 相似文献